Adopting the established clinical CEA threshold of 5 ng/mL to distinguish metastatic from non-metastatic CRC, serum CEA unveiled a sensitivity of 58.1%, a specificity of 78.0%, and an AUC of 0.615 (Figure S7). Here, CEACAM5 is linked to colorectal carcinoma.